China Biotech Services Holdings Limited

Equities

8037

BMG2152F1014

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. Other stock markets 04:08:39 2024-05-28 EDT			5-day change	1st Jan Change
0.35 ^HKD	-1.41%		+6.06%	-54.55%

03-28	China Biotech Services Holdings Limited Announces Not Recommends Final Dividend for the Year Ended 31 December 2023	CI
03-28	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2021

March 07, 2022 at 05:48 am

China Biotech Services Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2021. For the year, the company expected to record a consolidated net profit attributable to the owners of the Company of not less than HKD 17,000,000, as compared with that of approximately HKD 30,170,000 for the year ended 31 December 2020.

Latest news about China Biotech Services Holdings Limited

China Biotech Services Holdings Limited Announces Not Recommends Final Dividend for the Year Ended 31 December 2023	03-28	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding	03-24	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	02-28	CI
Pengbo Medical Technology Co., Ltd. Announces the Approval by the Hainan Provincial Medical Products Administration for the Import of Medical Devices	01-30	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2023	23-10-31	CI
China Biotech Services Holdings Limited Announces Strategic Cooperation Framework Agreement with Astrazeneca Investment Co., Ltd	23-10-18	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-08-01	CI
China Biotech Services Holdings Limited Announces Redesignation of Chui Hoi Yam from an Executive Director to Non-Executive Director	23-06-30	CI
China Biotech Services Holdings Limited Declares Final Dividend for the Year Ended 31 December 2022	23-05-16	CI
China Biotech Services Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
China Biotech Services Holdings Limited and The Chinese University of Hong Kong Enter into Memorandum of Understanding	23-05-02	CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Three Months Ended 31 March 2023	23-04-28	CI
China Biotech Services Holdings Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2022, Payable on 15 June 2023	23-03-24	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022	23-02-28	CI
China Biotech Services Holdings Limited announced that it has received HKD 77.8 million in funding from Guoyuan Securities Investment (Hong Kong) Limited	22-12-19	CI
China Biotech Services Holdings Limited Announces Board Changes	22-12-05	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Nine Months Ended 30 September 2022	22-11-04	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ending 30 June 2022	22-08-03	CI
China Biotech Services Holdings Limited Announces Management Changes	22-06-20	CI
China Biotech Services Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI

Chart China Biotech Services Holdings Limited

Duration

Period

Chart China Biotech Services Holdings Limited

More charts

Company Profile

China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Sector

Healthcare Facilities & Services

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CHINA BIOTECH SERVICES HOLDINGS LIMITED	-54.55%	43.8M
HCA HEALTHCARE, INC.	+17.55%	83.47B
CVS HEALTH CORPORATION	-32.13%	69.72B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-3.24%	26.37B
FRESENIUS SE & CO. KGAA	+4.13%	17.86B
LABCORP HOLDINGS INC.	-13.70%	16.83B
QUEST DIAGNOSTICS INCORPORATED	+0.70%	15.7B
NATERA, INC.	+74.94%	13.45B
TENET HEALTHCARE CORPORATION	+73.14%	12.81B
REDE D'OR SÃO LUIZ S.A.	-2.23%	12.44B

Other Healthcare Facilities & Services